Vivesto AB (VIVE.ST)
SEK 0.24
(1.5%)
SEK 0.24
(1.5%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 | -89.75 Million SEK | 8.06% |
| 2021 | -97.62 Million SEK | -748.96% |
| 2020 | -11.49 Million SEK | 0.0% |
| 2019 | -11.49 Million SEK | 89.87% |
| 2018 | -113.52 Million SEK | -14.87% |
| 2017 | -98.82 Million SEK | 30.52% |
| 2016 | -142.24 Million SEK | -10.7% |
| 2015 | -128.5 Million SEK | -24.88% |
| 2014 | -102.9 Million SEK | -5.86% |
| 2013 | -97.2 Million SEK | -51.13% |
| 2012 | -64.32 Million SEK | -6.36% |
| 2011 | -60.47 Million SEK | -2.16% |
| 2010 | -59.19 Million SEK | -441.2% |
| 2009 | -10.93 Million SEK | 72.67% |
| 2008 | -40.02 Million SEK | -239.09% |
| 2007 | -11.8 Million SEK | -40.31% |
| 2006 | -8.41 Million SEK | -33.83% |
| 2005 | -6.28 Million SEK | -308.37% |
| 2004 | 3.01 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q1 | -17.63 Million SEK | 22.37% |
| 2023 Q2 | -24.38 Million SEK | -38.32% |
| 2022 Q3 | -20.48 Million SEK | 30.08% |
| 2022 FY | - SEK | 8.06% |
| 2022 Q1 | -20.4 Million SEK | -509.6% |
| 2022 Q2 | -29.29 Million SEK | -43.58% |
| 2022 Q4 | -22.71 Million SEK | -10.89% |
| 2021 Q1 | -32.14 Million SEK | 82.74% |
| 2021 Q4 | 4.98 Million SEK | 119.03% |
| 2021 Q2 | -48.71 Million SEK | -51.58% |
| 2021 Q3 | -26.17 Million SEK | 46.28% |
| 2021 FY | - SEK | -748.96% |
| 2020 Q1 | 118.03 Million SEK | 319.03% |
| 2020 Q2 | -39.59 Million SEK | -133.55% |
| 2020 Q3 | -41.9 Million SEK | -5.82% |
| 2020 Q4 | -186.17 Million SEK | -344.32% |
| 2020 FY | - SEK | 0.0% |
| 2019 Q1 | -42.48 Million SEK | -73.99% |
| 2019 Q4 | -53.88 Million SEK | -22.44% |
| 2019 FY | - SEK | 89.87% |
| 2019 Q3 | -44.01 Million SEK | -35.11% |
| 2019 Q2 | -32.57 Million SEK | 23.32% |
| 2018 Q2 | -25.28 Million SEK | 5.25% |
| 2018 FY | - SEK | -14.87% |
| 2018 Q4 | -24.41 Million SEK | -14.44% |
| 2018 Q1 | -26.68 Million SEK | -11.83% |
| 2018 Q3 | -21.33 Million SEK | 15.62% |
| 2017 Q2 | -27.27 Million SEK | 24.88% |
| 2017 Q4 | -23.86 Million SEK | -13.62% |
| 2017 FY | - SEK | 30.52% |
| 2017 Q3 | -21 Million SEK | 23.0% |
| 2017 Q1 | -36.31 Million SEK | -7.8% |
| 2016 FY | - SEK | -10.7% |
| 2016 Q1 | -30.87 Million SEK | -44.77% |
| 2016 Q4 | -33.68 Million SEK | 2.99% |
| 2016 Q3 | -34.72 Million SEK | -11.37% |
| 2016 Q2 | -31.17 Million SEK | -0.97% |
| 2015 Q1 | -26.86 Million SEK | -11.96% |
| 2015 Q4 | -21.32 Million SEK | 46.39% |
| 2015 Q2 | -36.51 Million SEK | -35.93% |
| 2015 Q3 | -39.78 Million SEK | -8.94% |
| 2015 FY | - SEK | -24.88% |
| 2014 Q2 | -29.01 Million SEK | 14.72% |
| 2014 Q3 | -23 Million SEK | 20.69% |
| 2014 Q4 | -23.99 Million SEK | -4.28% |
| 2014 Q1 | -34.01 Million SEK | -25.05% |
| 2014 FY | - SEK | -5.86% |
| 2013 Q4 | -27.2 Million SEK | -69.1% |
| 2013 Q3 | -16.08 Million SEK | -2.77% |
| 2013 Q2 | -15.65 Million SEK | 23.51% |
| 2013 Q1 | -20.46 Million SEK | -59.7% |
| 2013 FY | - SEK | -51.13% |
| 2012 Q3 | -42.38 Million SEK | -28.25% |
| 2012 Q4 | -12.81 Million SEK | 69.76% |
| 2012 FY | - SEK | -6.36% |
| 2012 Q1 | -18.48 Million SEK | -16.28% |
| 2012 Q2 | -33.04 Million SEK | -78.76% |
| 2011 Q4 | -15.89 Million SEK | -1083.77% |
| 2011 FY | - SEK | -2.16% |
| 2011 Q1 | -20.25 Million SEK | -43.25% |
| 2011 Q2 | -13.97 Million SEK | 31.01% |
| 2011 Q3 | -1.34 Million SEK | 90.39% |
| 2010 Q2 | -10.13 Million SEK | -139.27% |
| 2010 Q3 | -14.66 Million SEK | -44.76% |
| 2010 Q4 | -14.13 Million SEK | 3.61% |
| 2010 FY | - SEK | -441.2% |
| 2010 Q1 | -4.23 Million SEK | 60.39% |
| 2009 Q4 | -10.69 Million SEK | -36.47% |
| 2009 Q2 | 11.82 Million SEK | 0.0% |
| 2009 Q3 | -7.83 Million SEK | -166.27% |
| 2009 FY | - SEK | 72.67% |
| 2008 FY | - SEK | -239.09% |
| 2007 FY | - SEK | -40.31% |
| 2006 FY | - SEK | -33.83% |
| 2005 FY | - SEK | -308.37% |
| 2004 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | -555.599% |
| AlzeCure Pharma AB (publ) | -37.86 Million SEK | -137.029% |
| BioGaia AB (publ) | 466.19 Million SEK | 119.254% |
| Enzymatica AB (publ) | -41.12 Million SEK | -118.272% |
| Enorama Pharma AB (publ) | -43.05 Million SEK | -108.483% |
| Gabather AB (publ) | 37 Thousand SEK | 242689.189% |
| Klaria Pharma Holding AB (publ.) | -14.77 Million SEK | -507.705% |
| Moberg Pharma AB (publ) | -26.95 Million SEK | -232.938% |
| Nanexa AB (publ) | -70.79 Million SEK | -26.793% |
| Newbury Pharmaceuticals AB (publ) | -12.34 Million SEK | -627.374% |
| ODI Pharma AB | 1.36 Million SEK | 6664.314% |
| Orexo AB (publ) | -22 Million SEK | -307.991% |
| Probi AB (publ) | 115.61 Million SEK | 177.637% |
| Swedencare AB (publ) | 484 Million SEK | 118.545% |
| Swedish Orphan Biovitrum AB (publ) | 7.23 Billion SEK | 101.241% |
| Toleranzia AB | -7.39 Million SEK | -1113.274% |